Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy

EuroIntervention

Volumn 9, Issue , 2013, Pages R29-R34

  Waeber, Bernard ^a   Feihl, François ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adherence; Antihypertensive therapy; Compliance; Drug intake; Monitoring; Refractory hypertension; Resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DRUG STORAGE; DRUG USE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HUMAN; INTERVIEW; MEDICATION COMPLIANCE; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; RESISTANT HYPERTENSION; REVIEW; TREATMENT WITHDRAWAL; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; HEART RATE; HYPERTENSION; PATHOPHYSIOLOGY; TREATMENT OUTCOME; DRUG EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DRUG MONITORING; DRUG RESISTANCE; HEART RATE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84888869334     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9SRA6     Document Type: Review

References (39)

1. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568-77.
2. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046-58.
3. Erdine S, Aran SN. Current status of hypertension control around the world. Clin Exp Hypertens. 2004;26:731-8.
4. Mancia G, Bombelli M, Lanzarotti A, Grassi G, Cesana G, Zanchetti A, Sega R. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med. 2002;162:582-6.
5. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension. 2001;38:827-32.
6. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10-7.
7. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998;317:167-71.
8. Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens. 2003;21:1635-40.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87.
11. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-26.
12. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, Amodeo C, Bortolotto LA, Krieger EM, Bradley TD, Lorenzi-Filho G. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811-7.
13. Mezzetti A, Pierdomenico SD, Costantini F, Romano F, Bucci A, Di Gioacchino M, Cuccurullo F. White-coat resistant hypertension. Am J Hypertens. 1997;10:1302-7.
14. Veglio F, Rabbia F, Riva P, Martini G, Genova GC, Milan A, Paglieri C, Carra R, Chiandussi L. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens. 2001;23:203-11.
15. Bunker J, Callister W, Chang CL, Sever PS. How common is true resistant hypertension? J Hum Hypertens. 2011;25:137-40.
16. Waeber B, Brunner HR, Metry JM. Compliance with antihypertensive treatment: implications for practice. Blood Press. 1997;6:326-31.
17. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357-62.
18. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995;130:572-9.
19. Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol. 1991;41:27-35.
20. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens. 1999;21:973-85.
21. Degoulet P, Menard J, Vu HA, Golmard JL, Devries C, Chatellier G, Plouin PF. Factors predictive of attendance at clinic and blood pressure control in hypertensive patients. Br Med J (Clin Res Ed). 1983;287:88-93.
22. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880-3.
23. Hershey JC, Morton BG, Davis JB, Reichgott MJ. Patient compliance with antihypertensive medication. Am J Public Health. 1980;70:1081-9.
24. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
25. Roth HP, Caron HS. Accuracy of doctors' estimates and patients' statements on adherence to a drug regimen. Clin Pharmacol Ther. 1978;23:361-70.
26. Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34:944-9.
27. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, Johnson AL. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1:1205-7.
28. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150:1377-8.
29. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther. 1991;13:489-95.
30. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care. 1994;32:214-26.
31. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10:697-704.
32. McKenney JM, Munroe WP, Wright JT Jr. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol. 1992;32:277-83.
33. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32:345-56.
34. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract. 1999;53:37-8.
35. Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, Lackland DT, Calhoun DA, Oparil S, Muntner P. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens. 2012;14:694-700.
36. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38:1363-8.
37. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31: 766-74.
38. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, Moreno H. Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension. J Clin Hypertens. 2009;11:183-91.
39. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens. 2001;19: 335-41.